Search

Your search keyword '"Long, Carole A."' showing total 911 results

Search Constraints

Start Over You searched for: Author "Long, Carole A." Remove constraint Author: "Long, Carole A."
911 results on '"Long, Carole A."'

Search Results

3. Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex

4. Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial

5. Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5

6. Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype

13. A randomized first-in-human phase I trial of differentially adjuvanted Pfs48/45 malaria vaccines in Burkinabe adults

14. Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults

21. Antibody gene features associated with binding and functional activity in malaria vaccine-derived human mAbs.

22. Cross-reactivity of rPvs48/45, a recombinant Plasmodium vivax protein, with sera from Plasmodium falciparum endemic areas of Africa

23. First Phase 1b, single-center, age de-escalation trial of theP. falciparumblood-stage malaria vaccine candidate RH5.1/Matrix-M™: a delayed boost regimen induces high levels of functional antibodies in 5-17 month old Tanzanian infants

26. Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control

28. Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination

29. Protein/AS01B vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors

30. NAD activates olfactory receptor 1386 to regulate type I interferon responses in Plasmodium yoelii YM infection.

31. A Self-Assembling Pfs230D1-Ferritin Nanoparticle Vaccine Has Potent and Durable Malaria Transmission-Reducing Activity.

32. A randomized first-in-human Phase 1 trial of differentially adjuvanted Pfs48/45 malaria vaccines in Burkinabé adults

33. Evaluation of Precision of thePlasmodium knowlesiGrowth Inhibition Assay forPlasmodium vivaxDuffy-Binding Protein-based Malaria Vaccine Development

34. Preclinical Development of a Stabilized RH5 Virus-Like Particle Vaccine that Induces Improved Anti-Malarial Antibodies

36. OA-344 Clinical development in Burkina Faso of novel malaria vaccines based on the Pfs48/45 antigen

37. Artemisinin resistance phenotypes and K13 inheritance in a Plasmodium falciparum cross and Aotus model

39. Autoantibodies inhibit Plasmodium falciparum growth and are associated with protection from clinical malaria

40. Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria.

41. Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5

42. Dysfunction of CD169 + macrophages and blockage of erythrocyte maturation as a mechanism of anemia in Plasmodium yoelii infection

46. Correction to: Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control

Catalog

Books, media, physical & digital resources